INTERVIEW: Oraya doesn't see threat from new AMD drugs
This article was originally published in Scrip
Executive Summary
US medical device company Oraya Therapeutics is ramping up commercialization of its radiotherapy product for age-related macular degeneration (AMD) – a treatment that looks set to disrupt a market currently dominated by drug giants Novartis and Roche with their anti-VEGF drug Lucentis (ranibizumab). Even the advent of the newer AMD drugs, such as Regeneron's approved anti-VEGF therapy Eylea (aflibercept injection) and Ophthotech's investigational platelet-derived growth factor (PGDF) inhibitor Fovista, leaves Oraya unperturbed.